Table 1.
Patient’s characteristics
| Study | Country | Year | Study design | Inclusion Criteria | N° open/tot | study period | M/F | Age (mean) | Aetiology (%) | APACHE IIa | CT Severityb | ICU admission (%) | Comorbidities | Organ Failure at presentation (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Husu et al. [26] | Finland | 2020 | Retrospective cohort | Primary open surgical necrosectomy for pancreatic necrosis | 109 | 2006–2017 | 96/13 | 52 (42–61) |
A 62(56.9) B 25(22.9) I 11(10.1) Hyper trig 0 O 11(10.1) |
Nr | Nr | 44 (40.4) |
CV 22 P 10 CRI 4 D 11 OT 5 |
12 (11.0) |
| Martinez et al. [27] | USA | 2019 | Rretrospective cohort | Primary open surgical necrosectomy for pancreatic necrosis | 34/56 | 2007–2016 | 24/10 | 55.9 ± 14.4 |
A 4(11.8) B 16(47.1) I 0 Hyper trig 4(11.8) O 10(29.4) |
Nr | Nr | Nr |
Acute renal F 18 (52.9) Acute respiratory F 18 (52.9) |
multiple 16 (47,1) |
| Cao et al. [28] | China | 2019 | Retrospective cohort | Primary open surgical necrosectomy for infected pancreatic necrosis | 45 | 2015–2017 | 32/13 | 51.89 ± 12.92 |
A 6 (13.3) B 16 (35.6) H 20 (44.4) O 3 (6.7) |
Nr | 9 ± 1.1 | Nr |
CV 22 P 1 CRI 2 D 8 OT / |
single 17 (37.8) multiple 7 (15.6) |
| Šileikis et al [29] | Lithuania | 2017 | Retrospective cohort | Primary open surgical necrosectomy for pancreatic necrosis | 53/95 | 2007–2016 | 34/19 | 56.5 ± 16.1 | Nr | Nr | 7.6 ± 1.9 | Nr | Nr | multiple 41 (77.4) |
| Wroński et al [30] | Poland | 2017 | Retrospective cohort | Primary open surgical necrosectomy for pancreatic necrosis | 22/70 | 2007–2014 | 16/6 | 49 (36–61) |
A 12(54.6) B 4 (18.2) O 6 (27.3) |
Nr | 8 (6–10) | Nr | Nr | 4 (18.2) |
| Rash et al [31] | Germany | 2016 | Retrospective multicenter cohort | Primary open surgical necrosectomy in severe pancreatitis | 30/220 | 2008–2014 | 2.3:1 | 55 (18 ± 82) | Nr | Nr | Nr | Nr | Nr | 25 (73.3) |
| Gomatos et al [32] | UK | 2016 | Retrospective cohort | Primary open surgical necrosectomy for pancreatic necrosis | 120 | 1997–2013 | 86/34 | 58.5 (42–70) |
A 53 (44.2) B 37 (30.8) I 5 (4.2) O 25 (20.8) |
8 | 7 | 36 (30) | Nr | multiple 30 (25) |
| Barreda et al. [33] | Perù | 2015 | Retrospective cohort | Primary open surgical necrosectomy in emphysematous necrotizing pancreatitis (gas within the pancreatic necrosis on CT) | 36/56 | 2003–2011 | nr | 54 (16–80) |
A 4 (7.1) B 46(82.1) I 3(5.4) Hyper trig 2 (3.6) O 1(1.8) |
14 (6–28) | 9.4 (8–10) | Nr | Nr |
single 30 (83.3) multiple 21 (58.3) |
| Pupelis G et al [34] | Latvia | 2014 | Prospective cohort | Primary open surgical necrosectomy for infected pancreatic necrosis | 39/70 | 2004–2014 | 32/7 | 47 (41–62) |
A 23 (59) B 6(15.4) O 10 (25.6) |
12 (7–18) | 8 (6-10) | Nr | ASA III 31 (79.5%) | multiple 15 (38.5) |
| Tan V et al [35] | France | 2014 | Retrospective multicenter cohort | Primary open surgical necrosectomy for infected pancreatic necrosis | 21/32 | 2005–2011 | 14/7 | 52(47–60) |
A 6 (28.6) B 6(28.6) O 9 (42.8) |
12 (10–16) | 6 (5—6) | Nr |
CV 14 D 5 OT 9 |
13 (60) |
| Madenci et al [36] | USA | 2014 | Retrospective cohort | Primary open surgical necrosectomy for pancreatic necrosis | 68 | 2006–2009 | 48/20 | 54.2 ± 1.7 |
A 26 (38.2) B 19 (27.9) I 5(7.4) Hyper trig 5 (7.4) O 13(19.1) |
10.9 ± .8 | 7.6 ± .3 | 22 (32.3) | Nr | 24 (35.3) |
| Pascual et al [37] | Spain | 2013 | Retrospective cohort | Primary open surgical necrosectomy for infected pancreatic necrosis | 21/39 | 1998–2010 | 10/11 | 62.5 ± 14.6 |
A 3 (14.3) B 14 (66.7) I 0 O 4(19) |
10.6 ± 5.6 (r = 2–22) | 10 (6–10) | Nr | 11 (52.4 %) |
single 3 (14.3) multiple 11(52.4) |
| Tu et al [38] | China | 2012 | Retrospective cohort | Primary open surgical necrosectomy for infected Pancreatic necrosis | 32/50 | 2006–2012 | 19/23 | 48.7 (33–71) |
A 3 (9.4) B 28 (87.5) Hyper trig 1 (3.1) |
13.4 ± 5.2 | 5.3 ± 1.6 | Nr |
Hypovol 14 Hypox10 ARenalF3 Acute GH 1 |
Nr |
| Senthil Kumar et al [39] | India | 2012 | Retrospective cohort | Primary open surgical necrosectomy for suspected or confirmed infected necrosis | 15/30 | 2008–2011 | 15/0 | 41 (30–55) |
A 9 (60) B 5 (33.3) O 1 (6.7) |
9 (5–20) |
CTI 7 (3) CTI 8–10 (12) |
11 | Nr |
single 8 (53.3) multiple 2 (13.3) |
| Bausch et al [40] | Germany | 2012 | Retrospective cohort | Primary open surgical necrosectomy for pancreatic necrosis | 30/62 | 1998–2010 | 17/13 | 64 (25–88) |
A 5 (16.7) B 4 (13.3) I 2 (6.7) O 19 (63.3) |
Nr | Nr | Nr | Nr | multiple 22 (73.3) |
| Tan et al [41] | China | 2012 | Retrospective multicentre cohort | Primary open surgical necrosectomy for suspected or confirmed infected necrosis | 51/76 | 2008–2010 | 33/18 | 44.1 |
A 24 (31.5) B 30 (39.5) I 4 (5.3) O 18 (23.7) |
12.46–5.8 | 4.91–1.23 | Nr | Nr | Nr |
| Doctor et al [42] | India | 2011 | Retrospective cohort | Primary open surgical necrosectomy for infected pancreatic necrosis | 59/61 | 1998–2009 | 49/12 | 43(18–73) |
A 14 (23) B 25 (41) I 3 (4.9) O 19 (31.1) |
> 9 | ≥ 7 | 59 | Nr | Nr |
| Boland et al [43] | USA | 2010 | Retrospective cohort | Primary open surgical necrosectomy for infected pancreatic necrosis | 21 | 2002–2008 | 13/8 | 53 (28–86) |
A 3 (14.3) B 8 (38.1) I 4 (19.0) O 6 (28.6) |
Nr | Nr | Nr |
CV 7 (%) ARI 2 (%) D 5 (%) OT 4. |
9 (43) |
| Raraty et al [11] | UK | 2010 | Retrospective cohort | Primary open surgical necrosectomy for pancreatic necrosis | 28 | 2000–2008 | Nr | Nr | Nr | 10.5 (5–26) | Nr | Nr | Nr | Nr |
| van Santvoort et al [13] | Netherlands | 2010 | Multicentre randomized study | Primary open surgical necrosectomy for suspected or confirmed infected necrosis | 45/88 | 2005–2008 | 33/12 | 57.4 ± 2.0 |
A 5 (11) B 29 (64) O 11 (24) |
15.0 ± 5.3 | 8 (4–10) | 29 (64%) |
CV 21 (47%) P 4 (9%) CRI 2 (4%) D 4 (9%) OT/. ASA III 14 (31) |
single 22 (49) multiple 13 (29) |
aScores on the Acute Physiologic and Chronic Health Evaluation II (APACHE II) scale range from 0 to 71, with higher scores indicating more severe disease
bScores on the CT severity index range from 0 to 10, with higher scores indicating more extensive pancreatic necrosis and peripancreatic fluid collections
Nr not reported, A alcoholic, B biliary, I iatrogenic, Hyper trig hypertriglyceridemia, O other